vs
8X8 INC（EGHT）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
8X8 INC的季度营收约是再鼎医药的1.5倍（$185.1M vs $127.1M），再鼎医药同比增速更快（17.1% vs 3.4%），8X8 INC自由现金流更多（$19.1M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 1.6%）
8x8 Inc是源自美国的企业级云通信与客户体验软件服务商，依托云架构为企业提供统一通信、呼叫中心及通信平台即服务（CPaaS）等产品方案，公司总部位于加利福尼亚州坎贝尔，其股票在纳斯达克交易所挂牌交易。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
EGHT vs ZLAB — 直观对比
营收规模更大
EGHT
是对方的1.5倍
$127.1M
营收增速更快
ZLAB
高出13.7%
3.4%
自由现金流更多
EGHT
多$45.8M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
1.6%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.1M | $127.1M |
| 净利润 | $5.1M | — |
| 毛利率 | 63.9% | 51.0% |
| 营业利润率 | 5.2% | -54.6% |
| 净利率 | 2.8% | — |
| 营收同比 | 3.4% | 17.1% |
| 净利润同比 | 68.4% | — |
| 每股收益（稀释后） | $0.04 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EGHTZLAB
| Q4 25 | $185.1M | $127.1M | ||
| Q3 25 | $184.1M | $115.4M | ||
| Q2 25 | $181.4M | $109.1M | ||
| Q1 25 | $177.0M | $105.7M | ||
| Q4 24 | $178.9M | $108.5M | ||
| Q3 24 | $181.0M | $101.8M | ||
| Q2 24 | $178.1M | $100.1M | ||
| Q1 24 | $179.4M | $87.1M |
净利润EGHTZLAB
| Q4 25 | $5.1M | — | ||
| Q3 25 | $767.0K | $-36.0M | ||
| Q2 25 | $-4.3M | $-40.7M | ||
| Q1 25 | $-5.4M | $-48.4M | ||
| Q4 24 | $3.0M | — | ||
| Q3 24 | $-14.5M | $-41.7M | ||
| Q2 24 | $-10.3M | $-80.3M | ||
| Q1 24 | $-23.6M | $-53.5M |
毛利率EGHTZLAB
| Q4 25 | 63.9% | 51.0% | ||
| Q3 25 | 64.8% | 59.5% | ||
| Q2 25 | 66.4% | 60.6% | ||
| Q1 25 | 67.8% | 63.6% | ||
| Q4 24 | 67.7% | 61.5% | ||
| Q3 24 | 68.1% | 64.1% | ||
| Q2 24 | 67.9% | 64.9% | ||
| Q1 24 | 68.2% | 61.4% |
营业利润率EGHTZLAB
| Q4 25 | 5.2% | -54.6% | ||
| Q3 25 | 2.9% | -42.3% | ||
| Q2 25 | 0.3% | -50.3% | ||
| Q1 25 | 0.2% | -53.3% | ||
| Q4 24 | 5.0% | -62.6% | ||
| Q3 24 | 4.0% | -66.6% | ||
| Q2 24 | -0.8% | -76.0% | ||
| Q1 24 | -7.9% | -80.7% |
净利率EGHTZLAB
| Q4 25 | 2.8% | — | ||
| Q3 25 | 0.4% | -31.2% | ||
| Q2 25 | -2.4% | -37.3% | ||
| Q1 25 | -3.1% | -45.8% | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | -8.0% | -40.9% | ||
| Q2 24 | -5.8% | -80.2% | ||
| Q1 24 | -13.1% | -61.4% |
每股收益（稀释后）EGHTZLAB
| Q4 25 | $0.04 | $-0.05 | ||
| Q3 25 | $0.01 | $-0.03 | ||
| Q2 25 | $-0.03 | $-0.04 | ||
| Q1 25 | $-0.04 | $-0.04 | ||
| Q4 24 | $0.02 | $-0.09 | ||
| Q3 24 | $-0.11 | $-0.04 | ||
| Q2 24 | $-0.08 | $-0.08 | ||
| Q1 24 | $-0.20 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $86.9M | $689.6M |
| 总债务越低越好 | $321.2M | — |
| 股东权益账面价值 | $142.9M | $715.5M |
| 总资产 | $661.5M | $1.2B |
| 负债/权益比越低杠杆越低 | 2.25× | — |
8季度趋势，按日历期对齐
现金及短期投资EGHTZLAB
| Q4 25 | $86.9M | $689.6M | ||
| Q3 25 | $75.9M | $717.2M | ||
| Q2 25 | $81.3M | $732.2M | ||
| Q1 25 | $88.0M | $757.3M | ||
| Q4 24 | $104.2M | $779.7M | ||
| Q3 24 | $117.4M | $616.1M | ||
| Q2 24 | $130.8M | $630.0M | ||
| Q1 24 | $117.3M | $650.8M |
总债务EGHTZLAB
| Q4 25 | $321.2M | — | ||
| Q3 25 | $325.8M | — | ||
| Q2 25 | $335.4M | — | ||
| Q1 25 | $350.0M | — | ||
| Q4 24 | $364.5M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $409.7M | — |
股东权益EGHTZLAB
| Q4 25 | $142.9M | $715.5M | ||
| Q3 25 | $133.2M | $759.9M | ||
| Q2 25 | $128.2M | $791.7M | ||
| Q1 25 | $122.2M | $810.8M | ||
| Q4 24 | $113.0M | $840.9M | ||
| Q3 24 | $109.8M | $667.7M | ||
| Q2 24 | $104.6M | $704.2M | ||
| Q1 24 | $102.0M | $762.2M |
总资产EGHTZLAB
| Q4 25 | $661.5M | $1.2B | ||
| Q3 25 | $670.8M | $1.2B | ||
| Q2 25 | $684.3M | $1.2B | ||
| Q1 25 | $683.2M | $1.2B | ||
| Q4 24 | $698.2M | $1.2B | ||
| Q3 24 | $740.1M | $985.3M | ||
| Q2 24 | $755.7M | $987.4M | ||
| Q1 24 | $756.0M | $988.4M |
负债/权益比EGHTZLAB
| Q4 25 | 2.25× | — | ||
| Q3 25 | 2.45× | — | ||
| Q2 25 | 2.62× | — | ||
| Q1 25 | 2.86× | — | ||
| Q4 24 | 3.23× | — | ||
| Q3 24 | 3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 4.02× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.7M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $19.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | 10.3% | -21.0% |
| 资本支出强度资本支出/营收 | 0.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.07× | — |
| 过去12个月自由现金流最近4个季度 | $43.8M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流EGHTZLAB
| Q4 25 | $20.7M | $-26.0M | ||
| Q3 25 | $8.8M | $-32.0M | ||
| Q2 25 | $11.9M | $-31.0M | ||
| Q1 25 | $5.9M | $-61.7M | ||
| Q4 24 | $27.2M | $-55.8M | ||
| Q3 24 | $12.3M | $-26.8M | ||
| Q2 24 | $18.1M | $-42.2M | ||
| Q1 24 | $12.7M | $-90.1M |
自由现金流EGHTZLAB
| Q4 25 | $19.1M | $-26.7M | ||
| Q3 25 | $7.7M | $-35.0M | ||
| Q2 25 | $11.5M | $-33.9M | ||
| Q1 25 | $5.5M | $-63.2M | ||
| Q4 24 | $26.8M | $-58.4M | ||
| Q3 24 | $11.1M | $-28.2M | ||
| Q2 24 | $17.8M | $-42.9M | ||
| Q1 24 | $12.3M | $-91.1M |
自由现金流率EGHTZLAB
| Q4 25 | 10.3% | -21.0% | ||
| Q3 25 | 4.2% | -30.4% | ||
| Q2 25 | 6.3% | -31.1% | ||
| Q1 25 | 3.1% | -59.9% | ||
| Q4 24 | 15.0% | -53.8% | ||
| Q3 24 | 6.1% | -27.7% | ||
| Q2 24 | 10.0% | -42.9% | ||
| Q1 24 | 6.9% | -104.5% |
资本支出强度EGHTZLAB
| Q4 25 | 0.9% | 0.5% | ||
| Q3 25 | 0.6% | 2.6% | ||
| Q2 25 | 0.2% | 2.6% | ||
| Q1 25 | 0.2% | 1.5% | ||
| Q4 24 | 0.3% | 2.4% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 0.2% | 0.7% | ||
| Q1 24 | 0.2% | 1.1% |
现金转化率EGHTZLAB
| Q4 25 | 4.07× | — | ||
| Q3 25 | 11.52× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 9.01× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EGHT
| Services | $179.7M | 97% |
| Other | $5.4M | 3% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
